{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T20:48:44Z","timestamp":1777927724716,"version":"3.51.4"},"reference-count":82,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDRR"],"published-print":{"date-parts":[[2021,1,11]]},"abstract":"<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p> Dithranol (DTH) is a well-known moiety that has long been used promisingly\nto impede and treat skin disorders, particularly psoriasis. Nowadays, a rekindled interest in the use\nof DTH for this disorder has been observed. Side effects associated with conventional topical formulations\nof this moiety have aroused the interest of the scientific community in investigating novel\ncargos of DTH for psoriasis management.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Previous research has evidenced the anti-inflammatory and anti-proliferating potential of\nDTH. Numerous studies have indicated that DTH inhibits polymorphonuclear (PMN) leucocyte,\nmodulates epidermal cell receptors and promotes anti-psoriatic action. However, some deterrent factors\nlike poor solubility, stability, toxicity, staining and skin irritation hamper its use as a potential\ntherapeutic agent. With the adoption of novel drug delivery technologies, the above mentioned inherent\nlimitations of DTH have been compensated to reestablish this drug moiety.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p> This article reviews novel drug delivery aspects, safety concerns, clinical evidence,\ncurrent status, and future opportunities of DTH in the management of psoriasis. Further, it will update\nresearchers on this promising drug moiety, which is free from systemic adverse responses in\ncomparison to other therapeutic molecules like steroids, for psoriasis treatment.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/2589977512666200525154954","type":"journal-article","created":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T12:59:41Z","timestamp":1590411581000},"page":"82-96","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Dithranol: An Insight into its Novel Delivery Cargos for Psoriasis Management"],"prefix":"10.2174","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4328-9118","authenticated-orcid":true,"given":"Varsha","family":"Kadian","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, Guru Jambheshwar University of Science and Technology, Hisar-125001, Haryana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4466-3215","authenticated-orcid":true,"given":"Sunil","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Guru Jambheshwar University of Science and Technology, Hisar-125001, Haryana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4342-0681","authenticated-orcid":true,"given":"Komal","family":"Saini","sequence":"additional","affiliation":[{"name":"University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh-160014, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3325-781X","authenticated-orcid":true,"given":"Vandita","family":"Kakkar","sequence":"additional","affiliation":[{"name":"University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh-160014, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0525-4064","authenticated-orcid":true,"given":"Rekha","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Guru Jambheshwar University of Science and Technology, Hisar-125001, Haryana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0190-9622(83)70125-8","volume":"9","author":"Ashton R.E.","year":"1983","unstructured":"Ashton R.E.; Andre P.; Lowe N.J.; Whitefield M.; Anthralin: Historical and current perspectives. JAAD 1983,9(2),173-192","journal-title":"JAAD"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"446","DOI":"10.3390\/pharmaceutics12050446","volume":"12","author":"Fathalla D.","year":"2020","unstructured":"Fathalla D.; Youssef E.M.K.; Soliman G.M.; Liposomal and ethosomal gels for the topical delivery of anthralin: preparation, comparative evaluation and clinical assessment in psoriatic patients. Pharmaceutics 2020,12(5),446","journal-title":"Pharmaceutics"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"e449","DOI":"10.1111\/j.1365-4632.2012.05611.x","volume":"53","author":"Sehgal V.N.","year":"2014","unstructured":"Sehgal V.N.; Verma P.; Khurana A.; Anthralin\/dithranol in dermatology. Int J Dermatol 2014,53(10),e449-e460","journal-title":"Int J Dermatol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000210836","volume":"3","author":"Kem\u00e9ny L.","year":"1990","unstructured":"Kem\u00e9ny L.; Ruzicka T.; Braun-Falco O.; Dithranol: A review of the mechanism of action in the treatment of psoriasis vulgaris. Skin Pharmacol Physiol 1990,3(1),1-20","journal-title":"Skin Pharmacol Physiol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3109\/1061186X.2013.771778","volume":"21","author":"Agrawal U.","year":"2013","unstructured":"Agrawal U.; Mehra N.K.; Gupta U.; Jain N.K.; Hyperbranched dendritic nano-carriers for topical delivery of dithranol. J Drug Target 2013,21(5),497-506","journal-title":"J Drug Target"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/gme.0b013e3181b63c68","volume":"17","author":"Liu P.","year":"2010","unstructured":"Liu P.; Lu Y.; Recker R.R.; Deng H.W.; Dvornyk V.; ALOX12 gene is associated with the onset of natural menopause in white women. Menopause Available from:  https:\/\/www.mayoclinic.org\/drugs-supplements\/ anthralin-topical-route\/description\/drg-20061896\n                    2010,17(1),152-156","journal-title":"Menopause"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1517\/17425247.5.2.235","volume":"5","author":"Su Y-H.","year":"2008","unstructured":"Su Y-H.; Fang J-Y.; Drug delivery and formulations for the topical treatment of psoriasis. Expert Opin Drug Deliv 2008,5(2),235-249","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=8","author":"Van Scott E.J.","year":"1981","unstructured":"Van Scott E.J.; Ruey J.Y.; inventors; assignee Dithranol compositions stabilized with alpha hydroxyacids United States patent US 1981","journal-title":"assignee Dithranol compositions stabilized with alpha hydroxyacids United States patent US"},{"key":"ref=9","author":"Ruey J.Y.","year":"1982","unstructured":"Ruey J.Y.; Van Scott E.J.; inventors; assignee Therapeutic compositions and vehicles for topical pharmaceuticals United States patent US 1982","journal-title":"assignee Therapeutic compositions and vehicles for topical pharmaceuticals United States patent US"},{"key":"ref=10","author":"Van Scott E.J.","year":"1983","unstructured":"Van Scott E.J.; Ruey J.Y.; inventors; assignee Stable dithranol compositions in anhydrous vehicles United States patent US 1983","journal-title":"assignee Stable dithranol compositions in anhydrous vehicles United States patent US"},{"key":"ref=11","author":"Grollier J.F.","year":"1985","unstructured":"Grollier J.F.; Rosenbaum G.; Allec J.; Shroot B.; inventors; assignee Composition in the form of a shampoo based on anthralin United States patent US 1985","journal-title":"assignee Composition in the form of a shampoo based on anthralin United States patent US"},{"key":"ref=12","author":"Grollier J.F.","year":"1985","unstructured":"Grollier J.F.; Rosenbaum G.; Allec J.; Shroot B.; inventors; assignee Anhydrous composition, stable to oxidation, based on anthralin or one of its derivatives, in a carrier consisting of a fatty acid alkyl ester and a thickener, and its use in the treatment of skin diseases United States patent US 1985","journal-title":"assignee Anhydrous composition, stable to oxidation, based on anthralin or one of its derivatives, in a carrier consisting of a fatty acid alkyl ester and a thickener, and its use in the treatment of skin diseases United States patent US"},{"key":"ref=13","author":"Yarrow H.","year":"1980","unstructured":"Yarrow H.; Whitefield M.; inventors; assignee Dithranol compositions for topical applications United States patent US 1980","journal-title":"assignee Dithranol compositions for topical applications United States patent US"},{"key":"ref=14","author":"Rosenberg E.W.","year":"1999","unstructured":"Rosenberg E.W.; Glenn T.M.; Skinner Jr RB; Noah P.W.; inventors; assignee Composition and method for treatment of psoriasis United States patent US Panda Pharmaceuticals LLC, University of Tennessee Research Foundation,1999","journal-title":"assignee Composition and method for treatment of psoriasis United States patent US"},{"key":"ref=15","author":"Wang J.C.","year":"1991","unstructured":"Wang J.C.; inventors; assignee Compositions and method for stabilization of anthralin comprising the addition of an oil soluble antioxidant and an anionic surfactant United States patent US Bristol Myers Squibb Co.1991","journal-title":"assignee Compositions and method for stabilization of anthralin comprising the addition of an oil soluble antioxidant and an anionic surfactant United States patent US"},{"key":"ref=16","author":"Whitefield M.","year":"1991","unstructured":"Whitefield M.; inventors; assignee  Dithranol composition containing no oily ingredients United States patent US Drythanol Ltd.1991","journal-title":"assignee  Dithranol composition containing no oily ingredients United States patent US"},{"key":"ref=17","author":"Schneider J.","year":"2002","unstructured":"Schneider J.; Wohlrab W.; Neubert R.; Huschka C.; Koegst D.; Fries G; inventors; assignee   Pharmaceutical preparation containing dithranol United States patent US esparma GmbH.2002","journal-title":"assignee   Pharmaceutical preparation containing dithranol United States patent US"},{"key":"ref=18","author":"Rosenberg E.W.","year":"1999","unstructured":"Rosenberg E.W.; Glenn T.M.; Skinner Jr RB; Noah P.W.; inventors; assignee Composition and method for treatment of psoriasis United States patent US Panda Pharmaceuticals LLC., University of Tennessee Research Foundation1999","journal-title":"assignee Composition and method for treatment of psoriasis United States patent US"},{"key":"ref=19","author":"Evans F.J.","year":"2000","unstructured":"Evans F.J.; Taylor E.J.;  Chalcone plant extracts for use in therapy Available from:  https:\/\/patents.google.com\/ patent\/EP0998939A1\/en\n                    2000","journal-title":"Chalcone plant extracts for use in therapy"},{"key":"ref=20","author":"Van Scott E.J.","year":"2002","unstructured":"Van Scott E.J.; Ruey J.Y.; inventors; Method for topical treatment of anthralin-responsive dermatological disorders United States patent US 2002","journal-title":"Method for topical treatment of anthralin-responsive dermatological disorders United States patent US"},{"key":"ref=21","author":"Gidwani S.K.","year":"2003","unstructured":"Gidwani S.K.; Singnurkar P.S.; inventors; assignee Composition for delivery of dithranol United States patent application US USV Pvt Ltd.2003","journal-title":"assignee Composition for delivery of dithranol United States patent application US"},{"key":"ref=22","author":"Katare O.P.","year":"2008","unstructured":"Katare O.P.; Agarwal R.; Kumar B.; inventors; assignee Novel Inter and Intra Multilamellar Vesicular Composition United States patent application US Lifecare Innovations Pvt Ltd2008","journal-title":"assignee Novel Inter and Intra Multilamellar Vesicular Composition United States patent application US"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0939-6411(98)00024-1","volume":"46","author":"Thoma K.","year":"1998","unstructured":"Thoma K.; Holzmann C.; Photostability of dithranol. Eur J Pharm Biopharm 1998,46(2),201-208","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1590\/S1984-82502014000300018","volume":"50","author":"Estanqueiro M.","year":"2014","unstructured":"Estanqueiro M.; Concei\u00e7\u00e3o J.; Amaral M.H.; Lobo J.M.S.; Use of solid dispersions to increase stability of dithranol in topical formulations. Braz J Pharm Sci 2014,50(3),583-590","journal-title":"Braz J Pharm Sci"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1080\/09546630260199479","volume":"13","author":"Saraswat A.","year":"2002","unstructured":"Saraswat A.; Agarwal R.; Kaur I.; Katare O.P.; Kumar B.; Fabric-staining properties and washability of a novel liposomal dithranol formulation. J Dermatolog Treat 2002,13(3),119-122","journal-title":"J Dermatolog Treat"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0378-5173(01)00810-9","volume":"228","author":"Agarwal R.","year":"2001","unstructured":"Agarwal R.; Katare O.P.; Vyas S.P.; Preparation and in vitro evaluation of liposomal\/niosomal delivery systems for antipsoriatic drug dithranol. Int J Pharm 2001,228(1-2),43-52","journal-title":"Int J Pharm"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.ejpb.2008.02.003","volume":"69","author":"Guenther U.","year":"2008","unstructured":"Guenther U.; Smirnova I.; Neubert R.H.H.; Hydrophilic silica aerogels as dermal drug delivery systems--dithranol as a model drug. Eur J Pharm Biopharm 2008,69(3),935-942","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3109\/02652048.2010.546435","volume":"28","author":"Raza K.","year":"2011","unstructured":"Raza K.; Negi P.; Takyar S.; Shukla A.; Amarji B.; Katare O.P.; Novel dithranol phospholipid microemulsion for topical application: development, characterization and percutaneous absorption studies. J Microencapsul 2011,28(3),190-199","journal-title":"J Microencapsul"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1590\/S1984-82502011000300008","volume":"47","author":"Gambhire M.S.","year":"2011","unstructured":"Gambhire M.S.; Bhalekar M.R.; Gambhire V.M.; Statistical optimization of dithranol-loaded solid lipid nanoparticles using factorial design. Braz J Pharm Sci 2011,47(3),503-511","journal-title":"Braz J Pharm Sci"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3109\/02652048.2012.717115","volume":"30","author":"Raza K.","year":"2013","unstructured":"Raza K.; Katare O.P.; Setia A.; Bhatia A.; Singh B.; Improved therapeutic performance of dithranol against psoriasis employing systematically optimized nanoemulsomes. J Microencapsul 2013,30(3),225-236","journal-title":"J Microencapsul"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.msec.2014.10.011","volume":"46","author":"Savian A.L.","year":"2015","unstructured":"Savian A.L.; Rodrigues D.; Weber J.; Dithranol-loaded lipid-core nanocapsules improve the photostability and reduce the in vitro irritation potential of this drug. Mater Sci Eng C 2015,46,69-76","journal-title":"Mater Sci Eng C"},{"key":"ref=32","year":"2016","unstructured":"Global Report on Psoriasis World Health Organization2016","journal-title":"Global Report on Psoriasis"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"138","DOI":"10.5897\/AJPPX12.001","volume":"7","author":"Suresh P.K.","year":"2013","unstructured":"Suresh P.K.; Singh P.; Saraf S.; Novel topical drug carriers as a tool for treatment of psoriasis: progress and advances. Afr J Pharm Pharmacol 2013,7(5),138-147","journal-title":"Afr J Pharm Pharmacol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/jid.2011.365","volume":"132","author":"Langan S.M.","year":"2012","unstructured":"Langan S.M.; Seminara N.M.; Shin D.B.; Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol 2012,132(3),556-562","journal-title":"J Invest Dermatol"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0738-081X(97)00019-9","volume":"15","author":"Dithranol G.M.M.D.","year":"1997","unstructured":"Dithranol G.M.M.D.;  Clin Dermatol 1997,15(5),723-737","journal-title":"Clin Dermatol"},{"key":"ref=36","first-page":"83","volume":"186","author":"Mahrle G.","year":"1994","unstructured":"Mahrle G.; Bonnekoh B.; Wevers A.; Hegemann L.; Anthralin: how does it act and are there more favourable derivatives? Acta Derm Venereol Suppl (Stockh) 1994,186,83-84","journal-title":"Acta Derm Venereol Suppl (Stockh)"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/BF00376623","volume":"283","author":"Kem\u00e9ny L.","year":"1991","unstructured":"Kem\u00e9ny L.; Gross E.; Arenberger P.; Ruzicka T.; Dithranol-induced down-regulation of 12(S)-hydroxyeicosatetraenoic acid [12(S)-HETE] receptors in a human epidermal cell line. Arch Dermatol Res 1991,283(5),333-336","journal-title":"Arch Dermatol Res"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/1523-1747.ep12523566","volume":"87","author":"Schr\u00f6der J.","year":"1986","unstructured":"Schr\u00f6der J.; Christophers E.; Identification of C5ades arg and an anionic neutrophil-activating peptide (anap) in psoriatic scales. Jour of Inv Dermatol 1986,87(1),53-58","journal-title":"Jour of Inv Dermatol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/1523-1747.ep12696613","volume":"87","author":"Tucker W.F.","year":"1986","unstructured":"Tucker W.F.; MacNeil S.; Dawson R.A.; Tomlinson S.; Bleehen S.S.; An investigation of the ability of antipsoriatic drugs to inhibit calmodulin activity: a possible mode of action of dithranol (anthralin). J Invest Dermatol 1986,87(2),232-235","journal-title":"J Invest Dermatol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/S0006-2952(96)00732-0","volume":"53","author":"M\u00fcller K.","year":"1997","unstructured":"M\u00fcller K.; Antipsoriatic and proinflammatory action of anthralin. Implications for the role of oxygen radicals. Biochem Pharmacol 1997,53(9),1215-1221","journal-title":"Biochem Pharmacol"},{"key":"ref=41","volume":"5","author":"Majid I.","year":"2012","unstructured":"Majid I.; Keen A.; Management of alopecia areata: an update. Br J Med Pract 2012,5(3)","journal-title":"Br J Med Pract"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1080\/01932690903123726","volume":"30","author":"Carlotti M.E.","year":"2009","unstructured":"Carlotti M.E.; Sapino S.; Peira E.; Gallarate M.; Ugazio E.; On the photodegradation of dithranol in different topical formulations: use of SLN to increase the stability of the drug. J Dispers Sci Technol 2009,30(10),1517-1524","journal-title":"J Dispers Sci Technol"},{"key":"ref=43","first-page":"36","volume":"7","author":"Soliman G.M.","year":"2015","unstructured":"Soliman G.M.; Osman S.K.; Hamdan A.M.; Preparation and evaluation of anthralin biodegradable nanoparticles as a potential delivery system for the treatment of psoriasis. Int J Pharm Pharm Sci 2015,7(12),36-40","journal-title":"Int J Pharm Pharm Sci"},{"key":"ref=44","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2019.e01343","volume":"5","author":"Tripathi P.K.","year":"2019","unstructured":"Tripathi P.K.; Gorain B.; Choudhury H.; Srivastava A.; Kesharwani P.; Dendrimer entrapped microsponge gel of dithranol for effective topical treatment. Heliyon 2019,5(3)","journal-title":"Heliyon"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1080\/03639045.2019.1576722","volume":"45","author":"Sathe P.","year":"2019","unstructured":"Sathe P.; Saka R.; Kommineni N.; Raza K.; Khan W.; Dithranol-loaded nanostructured lipid carrier-based gel ameliorate psoriasis in imiquimod-induced mice psoriatic plaque model. Drug Dev Ind Pharm 2019,45(5),826-838","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1002\/jps.2600600902","volume":"60","author":"Chiou W.L.","year":"1971","unstructured":"Chiou W.L.; Riegelman S.; Pharmaceutical applications of solid dispersion systems. J Pharm Sci 1971,60(9),1281-1302","journal-title":"J Pharm Sci"},{"key":"ref=47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.2001438","volume":"15","author":"Fusenig N.E.","year":"2017","unstructured":"Fusenig N.E.; Capes-Davis A.; Bianchini F.; Sundell S.; Lichter P.; The need for a worldwide consensus for cell line authentication: Experience implementing a mandatory requirement at the international journal of cancer. PLoS Biol 2017,15(4)","journal-title":"PLoS Biol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/j.1365-2133.1989.tb01326.x","volume":"120","author":"Remitz A.","year":"1989","unstructured":"Remitz A.; kariniemi A, lehtonen E, nordling S. Inhibition of proliferation of HeLa cells by dithranol (anthralin) and 10-butyryl dithranol (butantrone). Br J Dermatol 1989,120(4),525-531","journal-title":"Br J Dermatol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/BF00375727","volume":"282","author":"Bonnekoh B.","year":"1990","unstructured":"Bonnekoh B.; Farkas B.; Geisel J.; Mahrle G.; Lactate dehydrogenase release as an indicator of dithranol-induced membrane injury in cultured human keratinocytes. A time profile study. Arch Dermatol Res 1990,282(5),325-329","journal-title":"Arch Dermatol Res"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/BF01105083","volume":"287","author":"Ockenfels H.M.","year":"1995","unstructured":"Ockenfels H.M.; Nussbaum G.; Schultewolter T.; Burger P.M.; Goos M.; Cyclosporin A.; Cyclosporin A.; FK506 and dithranol after tyrosine-specific protein phosphorylation in HaCaT keratinocytes. Arch Dermatol Res 1995,287(3-4),304-309","journal-title":"Arch Dermatol Res"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/j.1365-2133.1997.tb02138.x","volume":"136","author":"Mrowietz U.","year":"1997","unstructured":"Mrowietz U.; Jessat H.; Schwarz A.; Schwarz T.; Anthralin (dithranol) in vitro inhibits human monocytes to secrete IL-6, IL-8 and TNF-\u03b1, but not IL-1. Br J Dermatol 1997,136(4),542-547","journal-title":"Br J Dermatol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s000110050723","volume":"50","author":"Farkas A.","year":"2001","unstructured":"Farkas A.; Kem\u00e9ny L.; Sz\u00f6ny B.J.; Dithranol upregulates IL-10 receptors on the cultured human keratinocyte cell line HaCaT. Inflamm Res 2001,50(1),44-49","journal-title":"Inflamm Res"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1096\/fj.04-2664fje","volume":"19","author":"McGill A.","year":"2005","unstructured":"McGill A.; Frank A.; Emmett N.; Turnbull D.M.; Birch-Machin M.A.; Reynolds N.J.; The anti-psoriatic drug anthralin accumulates in keratinocyte mitochondria, dissipates mitochondrial membrane potential, and induces apoptosis through a pathway dependent on respiratory competent mitochondria. FASEB J 2005,19(8),1012-1014","journal-title":"FASEB J"},{"key":"ref=54","volume":"8","author":"Tencomnao T.","year":"2009","unstructured":"Tencomnao T.; Ronpirin C.; Prasansuklab A.; Poovorawan Y.; Decreased EGFR mRNA expression in response to antipsoriatic drug dithranol in vitro. Afr J Biotechnol 2009,8(14)","journal-title":"Afr J Biotechnol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"412","DOI":"10.4238\/2012.February.17.3","volume":"11","author":"Ronpirin C.","year":"2012","unstructured":"Ronpirin C.; Tencomnao T.; Effects of the antipsoriatic drug dithranol on E2A and caspase-9 gene expression in vitro. Genet Mol Res 2012,11(1),412-420","journal-title":"Genet Mol Res"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"3290","DOI":"10.4238\/2012.September.12.12","volume":"11","author":"Ronpirin C.","year":"2012","unstructured":"Ronpirin C.; Tencomnao T.; Dithranol downregulates expression of Id1 mRNA in human keratinocytes in vitro. Genet Mol Res 2012,11(3),3290-3297","journal-title":"Genet Mol Res"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/jphp.12019","volume":"65","author":"George S.E.","year":"2013","unstructured":"George S.E.; Anderson R.J.; Haswell M.; Groundwater P.W.; An investigation of the effects of dithranol-induced apoptosis in a human keratinocyte cell line. J Pharm Pharmacol 2013,65(4),552-560","journal-title":"J Pharm Pharmacol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1039\/C4MB00739E","volume":"11","author":"Hollywood K.A.","year":"2015","unstructured":"Hollywood K.A.; Winder C.L.; Dunn W.B.; Exploring the mode of action of dithranol therapy for psoriasis: a metabolomic analysis using HaCaT cells. Mol Biosyst 2015,11(8),2198-2209","journal-title":"Mol Biosyst"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"3502","DOI":"10.1242\/jcs.174409","volume":"128","author":"Khalil H.","year":"2015","unstructured":"Khalil H.; Loukili N.; Regamey A.; Cuesta-Marban A.; Santori E.; Huber M.; The caspase-3-p120-RasGAP module generates a NF- B repressor in response to cellular stress. J Cell Sci 2015,128(18),3502-3513","journal-title":"J Cell Sci"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13104-018-3192-1","volume":"11","author":"Richardson A.","year":"2018","unstructured":"Richardson A.; Muir L.; Mousdell S.; Sexton D.; Jones S.; Howl J.; Modulation of mitochondrial activity in HaCaT keratinocytes by the cell penetrating peptide Z-Gly-RGD(DPhe)-mitoparan. BMC Res Notes 2018,11(1),82","journal-title":"BMC Res Notes"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.3109\/13880209.2014.976713","volume":"53","author":"Singh S.K.","year":"2015","unstructured":"Singh S.K.; Chouhan H.S.; Sahu A.N.; Narayan G.; Assessment of in vitro antipsoriatic activity of selected Indian medicinal plants. Pharm Biol 2015,53(9),1295-1301","journal-title":"Pharm Biol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jep.2006.04.023","volume":"108","author":"Tse W-P.","year":"2006","unstructured":"Tse W-P.; Che C-T.; Liu K.; Lin Z-X.; Evaluation of the anti-proliferative properties of selected psoriasis-treating Chinese medicines on cultured HaCaT cells. J Ethnopharmacol 2006,108(1),133-141","journal-title":"J Ethnopharmacol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s13238-017-0408-4","volume":"9","author":"Liu L.","year":"2018","unstructured":"Liu L.; Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins. Protein Cell 2018,9(1),15-32","journal-title":"Protein Cell"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"404","DOI":"10.2174\/1389200218666170306104042","volume":"18","author":"Thotakura N.","year":"2017","unstructured":"Thotakura N.; Kumar P.; Wadhwa S.; Raza K.; Katare P.; Dermatokinetics as an important tool to assess the bioavailability of drugs by topical nanocarriers. Curr Drug Metab 2017,18(5),404-411","journal-title":"Curr Drug Metab"},{"key":"ref=65","first-page":"111","author":"Schaefer H.","year":"1982","unstructured":"Schaefer H.; Schalla W.; Shroot B.;  Pharmacology and kinetics of anthralin 1982,111-118","journal-title":"Pharmacology and kinetics of anthralin"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/S0190-9622(87)70106-6","volume":"16","author":"Wang J.C.","year":"1987","unstructured":"Wang J.C.; Patel B.G.; Ehmann C.W.; Lowe N.; The release and percutaneous permeation of anthralin products, using clinically involved and uninvolved psoriatic skin. J Am Acad Dermatol 1987,16(4),812-821","journal-title":"J Am Acad Dermatol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1111\/j.1365-2133.1995.tb16947.x","volume":"132","author":"Snater E.","year":"1995","unstructured":"Snater E.; Janssen E.A.; van der Valk P.G.; van de Kerkhof P.C.; Transepidermal water vapour loss is not increased during and following dithranol irritation. Br J Dermatol 1995,132(6),908-912","journal-title":"Br J Dermatol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/0378-5173(80)90054-X","volume":"7","author":"Wester R.C.","year":"1980","unstructured":"Wester R.C.; Noonan P.K.; Relevance of animal models for percutaneous absorption. Int J Pharm 1980,7(2),99-110","journal-title":"Int J Pharm"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1001\/archderm.1972.01620050027004","volume":"105","author":"Gay M.W.","year":"1972","unstructured":"Gay M.W.; Moore W.J.; Morgan J.M.; Montes L.F.; Anthra toxicity. Arch Dermatol 1972,105(2),213-215","journal-title":"Arch Dermatol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2340\/0001555574295297","volume":"74","author":"Goodfield M.J.","year":"1994","unstructured":"Goodfield M.J.; Hull S.M.; Cunliffe W.J.; The systemic effect of dithranol treatment in psoriasis. Acta Derm Venereol 1994,74(4),295-297","journal-title":"Acta Derm Venereol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1055\/s-0028-1101621","volume":"7","author":"Ippen H.","year":"1959","unstructured":"Ippen H.; Der stoffwechsel des 1, 8\u2013dioxyanthrachinons1. Planta Med 1959,7(04),423-426","journal-title":"Planta Med"},{"key":"ref=72","first-page":"563","volume":"34","author":"Neill S.M.","year":"1984","unstructured":"Neill S.M.; Bugrein A.; Coulson I.H.; Greaves M.W.; Toxicologic study of anthralin in an aqueous cream formulation. Cutis 1984,34(6),563-566","journal-title":"Cutis"},{"key":"ref=73","first-page":"129","volume":"2","author":"Bajaj S.","year":"2012","unstructured":"Bajaj S.; Singla D.; Sakhuja N.; Stability testing of pharmaceutical products. J Appl Pharm Sci 2012,2(3),129-138","journal-title":"J Appl Pharm Sci"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1023\/A:1008739110004","volume":"21","author":"Wuis E.W.","year":"1999","unstructured":"Wuis E.W.; Burger D.M.; Beelen M.; Hekster Y.A.; Stability of dithranol in creams. Pharm World Sci 1999,21(6),275-277","journal-title":"Pharm World Sci"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1159\/000029933","volume":"13","author":"Prins M.","year":"2000","unstructured":"Prins M.; Swinkels O.; Bouwhuis S.; Dithranol in a cream preparation: disperse or dissolve? Skin Pharmacol and Phys 2000,13(5),273-279","journal-title":"Skin Pharmacol and Phys"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1046\/j.1365-2230.2002.01106.x","volume":"27","author":"Kirkup M.","year":"2002","unstructured":"Kirkup M.; Sabroe R.; Kavanagh G.; Twice-daily vs. once-daily inpatient dithranol for psoriasis. Clin Exp Dermatol 2002,27(8),695-699","journal-title":"Clin Exp Dermatol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1046\/j.1365-2133.2002.04920.x","volume":"147","author":"Hartman M.","year":"2002","unstructured":"Hartman M.; Prins M.; Swinkels O.; Cost-effectiveness analysis of a psoriasis care instruction programme with dithranol compared with UVB phototherapy and inpatient dithranol treatment. Br J Dermatol 2002,147(3),538-544","journal-title":"Br J Dermatol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1111\/j.1365-2133.2003.05653.x","volume":"149","author":"McBride S.R.","year":"2003","unstructured":"McBride S.R.; Walker P.; Reynolds N.J.; Optimizing the frequency of outpatient short-contact dithranol treatment used in combination with broadband ultraviolet B for psoriasis: a randomized, within-patient controlled trial. Br J Dermatol 2003,149(6),1259-1265","journal-title":"Br J Dermatol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1159\/000068289","volume":"16","author":"Yamamoto T.","year":"2003","unstructured":"Yamamoto T.; Nishioka K.; Alteration of the expression of Bcl-2, Bcl-x, Bax, Fas, and Fas ligand in the involved skin of psoriasis vulgaris following topical anthralin therapy. Skin Pharmacol Appl Skin Physiol 2003,16(1),50-58","journal-title":"Skin Pharmacol Appl Skin Physiol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1159\/000076019","volume":"17","author":"Wulff-Woesten A.","year":"2004","unstructured":"Wulff-Woesten A.; Ohlendorf D.; Henz B.M.; Haas N.; Dithranol in an emulsifying oil base (bio-wash-oil) for the treatment of psoriasis of the scalp. Skin Pharmacol Physiol 2004,17(2),91-97","journal-title":"Skin Pharmacol Physiol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/j.1468-3083.2005.01093.x","volume":"19","author":"Kucharekova M.","year":"2005","unstructured":"Kucharekova M.; Lieffers L.; van de Kerkhof P.; van der Valk P.; Dithranol irritation in psoriasis treatment: A study of 68 in patients. J Eur Acad Derm Vene 2005,19(2),176-179","journal-title":"J Eur Acad Derm Vene"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.advms.2016.01.001","volume":"61","author":"My\u015bliwiec H.","year":"2016","unstructured":"My\u015bliwiec H.; My\u015bliwiec P.; Baran A.; Flisiak I.; Dithranol treatment of plaque-type psoriasis increases serum TNF-like weak inducer of apoptosis (TWEAK). Adv Med Sci 2016,61(2),207-211","journal-title":"Adv Med Sci"}],"container-title":["Current Drug Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/182275","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/182275\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/182275","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T15:30:42Z","timestamp":1638804642000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/182275\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,11]]},"references-count":82,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,1,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/2589977512666200525154954","relation":{},"ISSN":["2589-9775"],"issn-type":[{"value":"2589-9775","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-11-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}